The coming Relenza quarterly sales results will be...

The coming Relenza quarterly sales results will be stunning.

Peter Cook told us he did a brilliant job settling the GSK law suit for $20million to normalise the BTA-GSK relationship, and many have posted there is a new GSK CEO who is very keen about Relenza. BTA shareholders have every reason to celebrate.

With the excellent management in BTA (thanks for this cliché guys) and the new GSK CEO, Andrew Witty, Relenza is going to claim its number 1 place in the sun, showing once and for all Peter Cook is worth every single options he was showered with. It will put to shame all you silly shareholders who voted down last year resolution to reward Peter Cook. An excellent management, a superior product and a normalised relationship with GSK - you have to be a real silly to think we cannot beat Roche. $10 share price - no problem - just wait for 12 months. Our expert valuer had already posted.

(Drums rolling please!) Here is the we site:

From http://www.roche.com/investors/ir_update/inv-update-2009-10-15.htm

(Another round of applause please). Here’s the figure Relenza will easily beat –

Quote: “Sales of Tamiflu in the third quarter totalled 994 million francs and Global sales of the antiinfluenza medicine Tamiflu (oseltamivir) totalled 2.0 billion Swiss francs in the first nine months